spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Signant Health Joins the Association of Clinical Research Organizations (ACRO) to Add a Technology Perspective to Conversations with Legislators and Industry Leaders about the Future of Clinical Research

Signant Health

As the 13th member company elected into ACRO, Signant Health bring its unique voice and views on patient-centricity and trial technology to the forefront

PHILADELPHIA, PA – November 21, 2019: Signant Health announced today that it has joined the non-profit Association of Clinical Research Organizations (ACRO). ACRO, a global coalition of research and technology companies, makes it their mission to advocate as the collective voice of the innovative clinical research industry to regulators and policymakers, educating stakeholders and shaping policies that foster efficient, effective and safe conduct of clinical research.

Founded in 2002, ACRO supports members by elevating their positions and goals to legislators, ensuring regulators such as the FDA, NIH, EMA, and lawmakers understand the nuances and intricacies faced by today’s clinical trial organizations. This work influenced some of the more important recent clinical trial regulations such as the 21st Century Cures Act and EU Clinical Trial Regulation. 

As the 13th member company elected into ACRO, Signant Health joins as one of the industry’s premier eCOA, eConsent, and clinical trial technology companies.

Mike Nolte, CEO of Signant Health, said “As a technology provider, Signant brings a unique perspective to ACRO, promoting collaboration across the industry to achieve our shared responsibility for advancing patient-centric clinical research. Aligned with our strategy and values, ACRO has prioritized conversations around patient safety, privacy, and technology’s impact on clinical trials, and we are excited to join with ACRO and its member companies to support policy and investment that ensure safe and efficient trials for patients everywhere.”

“Signant Health’s mission – ensuring the patient remains at the forefront of clinical trial design and execution, while advancing the efficiency of the clinical trial enterprise – is one shared by the member companies of ACRO,” said Executive Director, Doug Peddicord. “We are extremely pleased to welcome Signant as our newest member and look forward to working together to move our industry forward.”

To learn more about Signant Health visit https://signanthealth.com. For further information on ACRO, please visit https://www.acrohealth.org.  

Who Is Signant Health?

The best technology succeeds in the background. Signant Health provides solutions that simplify every step of the patient journey to make it easier for people to participate in, and for sites and study teams to run, clinical trials. Signant unites eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite – an evolution built on more than 20 years of proven clinical research technology. Our intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable hundreds of sponsors and CROs (including all Top 20 pharma) to extend the reach of drug development, expand patient opportunities and improve data quality – helping them bring life-changing therapies to our families and communities around the world. Take a significant step toward patient-centricity at signanthealth.com.

Contact:  media@signanthealth.com, +1 267.498.2350
phone +1 267 498 2300
email media@signanthealth.com
web https://signanthealth.com/
email 4000 Chemical Road Suite 300 Plymouth Meeting, PA 19462
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Drive for generics sees Korea increasingly attractive to international pharma

Amsterdam, 31st July 2019: Already home to more than 40 pharmaceutical multinationals, Korea is on course to become a global biotech and pharmaceutical hub by 2025, driven by the surge of international partnerships, biosimilars, an expansion in the export of finished formulations and a robust generics market.
More info >>


White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

Industry Events

Pharmapack Europe 2020

5-6 February 2020, Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France


More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement